September 1997 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
Anti-IL-1 treatments might help with certain types of hair loss in people with high inflammation.
8 citations
,
May 2018 in “The Journal of Allergy and Clinical Immunology”
Activating the Nrf2 pathway reduces inflammation and cell activation in human hair follicles, suggesting a potential treatment for certain hair loss conditions.
Some individuals do not respond to oral minoxidil for hair loss, despite it generally working by improving blood flow to hair follicles. Factors like metabolism, drug interactions, and individual variations in the drug's activation may influence its effectiveness.
Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.
A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.
ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.
Creatine may counteract minoxidil's hair growth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.